This study will evaluate the potential benefit of blocking inflammation during a heart attack
using an investigational anti-inflammatory medicine called SP16. The study will enroll 10
patients and all 10 patients will receive a standard dose of SP16.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Serpin Pharma, LLC Virginia Commonwealth University
Collaborators:
Serpin Pharma, LLC Virginia Commonwealth University